Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer:final survival analysis of a phase III randomized trial

摘要

A planned interim analysis of study EGF100151 prompted early termination of enrollment based on a longer time to progression with lapatinib and capecitabine than with capecitabine alone in patients with human epidermal growth factor receptor (HER)-2(+) previously treated advanced breast cancer or metastatic breast cancer (MBC). Here, we report final analyses of overall survival.